Multiply Labs

Robotic biomanufacturing infrastructure for precision, individualized drugs and cell therapies.

Website: https://www.multiplylabs.com/

PUBLIC
Name Multiply Labs
Tagline Robotic biomanufacturing infrastructure for precision, individualized drugs and cell therapies.
Headquarters San Francisco, California
Founded 2016
Stage Series A
Business Model Hardware + Software
Industry Deeptech
Technology Robotics
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding Label $10M+
Total Disclosed $41.3 million [The Pharma Letter]

Links

PUBLIC

Executive Summary

PUBLIC Multiply Labs is building robotic biomanufacturing infrastructure to automate the sterile, high-throughput production of individualized drugs and gene-modified cell therapies, a technical challenge that currently bottlenecks the scale-up of advanced therapeutics [NVIDIA Blog]. Founded in 2016 by Fred Parietti and Alice Melocchi, the company has evolved from a concept for 3D-printed personalized pills into a systems provider for industrial-scale cell therapy manufacturing [MIT News, November 2016]. Its core offering combines cloud-controlled modular robotic clusters, which mimic lab workflows through imitation learning, with Digital QC software for process control and compliance [Multiply Labs]. This hardware-plus-software approach targets pharmaceutical and biotech customers, deploying systems as a production capacity service.

The founding team's background in robotics and pharmaceutical science provides a relevant foundation for the complex integration challenge at hand. The company has secured significant institutional backing, raising approximately $41.3 million over multiple rounds from investors including Casdin Capital, Lux Capital, and Y Combinator [The Pharma Letter]. Its business model appears to center on selling robotic production capacity and systems to named customers like AstraZeneca and Legend Biotech, though specific commercial terms are not public. Over the next 12-18 months, the key indicators to monitor will be the scale of deployments from its established partnerships, the operational performance of its new manufacturing subsidiary in Italy, and the progression from pilot collaborations to broader commercial adoption within the cell therapy industry.

Data Accuracy: GREEN -- Confirmed by multiple independent public sources and company statements.

Taxonomy Snapshot

Axis Classification
Stage Series A
Business Model Hardware + Software
Industry / Vertical Deeptech
Technology Type Robotics
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding $10M+ (total disclosed ~$41,300,000)

Company Overview

PUBLIC

Multiply Labs emerged from the MIT ecosystem in 2016, founded by Fred Parietti and Alice Melocchi on a shared interest in robotics applied to pharmaceuticals [MIT News, November 2016]. The company's initial public wedge was a robotic system for printing customized pharmaceutical capsules, a concept profiled by MIT as a personalized medicine play targeting millennials [MIT News, November 2016]. Over the subsequent eight years, the company's focus evolved from individualized pills toward the broader, more complex challenge of industrial-scale biomanufacturing for cell and gene therapies.

Headquartered in San Francisco, the company has built what it describes as a unique robotic pharmaceutical manufacturing facility in the city, which serves as both a proof-of-concept and a production site [LinkedIn]. A key operational milestone was the establishment of Multiply Labs Italia, a manufacturing subsidiary in Turin, Italy, announced in early 2026 to serve growing European pharmaceutical customers [Multiply Labs]. The company's capital formation accelerated with a $25 million Series A round led by Casdin Capital in April 2021, followed by an $11.1 million early-stage round in April 2023 [The Pharma Letter].

Data Accuracy: GREEN -- Founding details confirmed by MIT News and company website. Funding rounds corroborated by The Pharma Letter. Headquarter and subsidiary information sourced from LinkedIn and company press releases.

Product and Technology

MIXED Multiply Labs builds robotic systems that replicate the sterile, manual workflows of a cell therapy lab, aiming to turn a process reliant on skilled technicians into a high-throughput, software-defined manufacturing line. The company's core offering is a cloud-controlled modular robotic cluster, a hardware and software platform designed to automate the precise, multi-step procedures required to manufacture individualized drugs and gene-modified cell therapies [Multiply Labs]. These systems are described as using 'imitation learning' to mimic the actions of human operators, executing protocols for tasks like cell washing, separation, and formulation within a controlled environment [PERPLEXITY SONAR PRO BRIEF]. The software layer, branded as Digital QC, provides process planning, real-time sensor monitoring, and automated electronic batch record generation, which the company states is compliant with FDA regulation 21 CFR Part 11 [Multiply Labs].

Key product surfaces and public deployments include:

  • Robotic Biomanufacturing Infrastructure. The primary hardware system, which the company configures into multi-arm clusters for industrial-scale production. The systems are built to be compatible with market-leading GMP instruments [Multiply Labs].
  • Digital QC Software. A cloud-based platform for orchestrating robotic workflows and creating comprehensive digital records, sold alongside the hardware [Multiply Labs].
  • Proof-of-Concept Facility. The company operates a robotic pharmaceutical manufacturing facility in San Francisco, which serves as a demonstration site and a production node [PERPLEXITY SONAR PRO BRIEF].
  • Strategic Integrations. Multiply Labs has publicly disclosed technology partnerships, including the use of NVIDIA's Isaac robotics platform and Omniverse simulation environment to scale system development [NVIDIA Blog].

Public evidence of commercial traction is anchored in named collaborations rather than detailed customer metrics. The company has announced an expanded partnership with Thermo Fisher Scientific to integrate its robotic technology with Thermo Fisher's instruments for end-to-end automation [Business Wire, 2024]. It is also collaborating with the Stanford Laboratory for Cell and Gene Medicine to deploy robotic systems for cell therapy manufacturing [Multiply Labs]. Named pharmaceutical customers include AstraZeneca, Legend Biotech, and Kyverna Therapeutics, with whom Multiply Labs has a pilot to automate production of a CAR T-cell therapy candidate [Multiply Labs, 2025] [Multiply Labs]. The company's establishment of a manufacturing subsidiary, Multiply Labs Italia, in Turin is framed as a response to growing demand from these European pharmaceutical customers [LinkedIn, retrieved 2026].

Data Accuracy: GREEN -- Product claims and partnerships are confirmed by company press releases, partner announcements (NVIDIA, Thermo Fisher), and customer collaboration announcements.

Market Research

PUBLIC The demand for advanced, automated manufacturing solutions is intensifying as the cell and gene therapy sector moves from clinical promise to commercial reality, with scalability and consistency emerging as the primary bottlenecks for a new generation of highly personalized medicines.

Third-party market sizing specifically for robotic biomanufacturing infrastructure is not publicly available. However, the addressable market can be contextualized by the growth of the underlying therapeutic categories it serves. The global cell therapy market is projected to reach $25.2 billion by 2030, growing at a compound annual growth rate (CAGR) of 15.5% from 2024 [Precedence Research, 2024]. The gene therapy market is forecast to expand at a similar pace, with estimates for 2030 ranging from $30 billion to over $45 billion across various analyst reports [Grand View Research, 2024], [Allied Market Research, 2024]. The advanced therapy medicinal products (ATMP) manufacturing market, a direct proxy for the production technology segment, is itself projected to exceed $15 billion by 2030 [Roots Analysis, 2024]. Multiply Labs operates within a critical sub-segment of this manufacturing market, targeting the automation of its most complex and labor-intensive workflows.

Cell Therapy Market (2030) | 25.2 | $B
Gene Therapy Market (2030) | 30 | $B
ATMP Manufacturing Market (2030) | 15 | $B

These analogous market figures, while broad, illustrate the significant and expanding economic activity in the sectors where robotic automation addresses a fundamental scaling constraint.

The primary demand driver is the transition of cell and gene therapies from boutique, hospital-based production to industrialized, commercial-scale manufacturing. Manual or semi-automated processes, which sufficed for clinical trials, are prone to variability, contamination risk, and extreme labor costs, creating a severe bottleneck for therapies targeting patient populations in the thousands or tens of thousands [NVIDIA Blog]. A secondary tailwind is the regulatory push for greater standardization and data integrity in biomanufacturing. Software like Multiply Labs' Digital QC, which is described as CFR Part 11 compliant for electronic records, directly addresses the Food and Drug Administration's emphasis on robust process control and data traceability in advanced therapy production [Multiply Labs].

Key adjacent markets include traditional pharmaceutical manufacturing automation, dominated by large-scale bioreactor and fill-finish systems from established players like Thermo Fisher Scientific and Sartorius. While these markets are mature, they represent a logical expansion path for robotic systems once proven in more complex cell therapy workflows. Substitute markets are less about alternative technologies and more about alternative operational models, such as large contract development and manufacturing organizations (CDMOs) investing in their own proprietary automation or continuing to scale via manual labor pools in lower-cost regions. The regulatory environment acts as both a barrier and a catalyst. Stringent Good Manufacturing Practice (GMP) requirements for sterile processing create a high compliance hurdle for new entrants but also protect established, validated solutions from rapid displacement.

Data Accuracy: YELLOW -- Market sizing is based on third-party analyst reports for adjacent sectors; the specific TAM for robotic biomanufacturing infrastructure is not independently verified.

Competitive Landscape

MIXED

Multiply Labs operates in a competitive environment defined by established automation incumbents, specialized bioprocess vendors, and a nascent field of robotics-focused challengers. The company's position is not defined by a single head-to-head rival but by its specific integration of modular robotics, cloud control, and pharmaceutical-grade software for advanced therapies.

Given that no direct, named competitors were identified in the available public sources, the analysis proceeds without a formal comparison table. The competitive map must be assembled from adjacent categories and inferred market segments.

In the broad automation space for life sciences, traditional industrial robotics leaders like ABB and FANUC offer general-purpose robotic arms used in packaging and logistics, but their systems are not purpose-built for the sterile, protocol-driven workflows of cell therapy manufacturing. More specialized bioprocess automation companies, such as Sartorius (through its acquisition of RoosterBio) and Thermo Fisher Scientific, provide integrated instruments and consumables for cell culture and processing. These firms are partners as much as competitors; Multiply Labs's expanded collaboration with Thermo Fisher, announced in 2024, explicitly aims to integrate robotic technology with Thermo Fisher's instruments to achieve end-to-end automation [Business Wire, 2024]. This suggests the competitive dynamic is often one of coopetition, where Multiply Labs provides the robotic orchestration layer atop established laboratory hardware.

Where the company appears to carve a defensible edge is in its full-stack approach combining hardware, cloud software, and regulatory compliance from a single vendor. The proprietary Digital QC software, which is described as CFR Part 11 compliant and capable of creating comprehensive electronic records, addresses a critical pain point in Good Manufacturing Practice (GMP) environments [Multiply Labs]. This software-hardware integration, built around "imitation learning" of lab technician workflows, creates a technical moat that is difficult for a pure-play robotics firm or a traditional bioprocess vendor to replicate quickly [PERPLEXITY SONAR PRO BRIEF]. The edge is durable if the company continues to accumulate proprietary process data and protocol libraries from deployments, but it is perishable if a major automation incumbent decides to build or acquire a similar integrated software platform.

The company's most significant exposure likely lies in sales and distribution channels, not in pure technology. Large pharmaceutical and biotech customers, such as the named partners AstraZeneca and Legend Biotech, typically have long-standing procurement relationships with giants like Sartorius, Danaher (Cytiva), and Thermo Fisher [Multiply Labs]. These incumbents have deep customer relationships, global service networks, and extensive product catalogs. Multiply Labs must either displace these vendors for core automation projects,a high-barrier sale,or successfully position itself as a complementary, must-have orchestration layer that those vendors lack. Failure to secure a dominant position as the preferred robotics integrator could see its technology marginalized or replicated by a partner-turned-competitor.

The most plausible 18-month scenario involves further industry consolidation around the automation of cell therapy manufacturing. If regulatory pressures for traceability and scalability intensify, Multiply Labs could emerge as the winner if its early deployments with Kyverna Therapeutics and at the Stanford GMP Facility demonstrate unambiguous improvements in throughput, consistency, and cost [Multiply Labs, 2025] [Multiply Labs]. Conversely, a traditional automation or bioprocess incumbent would be the loser if it fails to respond with a credible robotics software platform, ceding the high-value integration layer to specialists. The wildcard is whether a well-funded, pure-play robotics startup emerges with a similar focus on biomanufacturing, which would test Multiply Labs's first-mover advantage in building customer trust and regulatory documentation.

Data Accuracy: YELLOW -- Competitive analysis is inferred from adjacent market players and partnership announcements; no direct competitor names are publicly cited in company materials or coverage.

Opportunity

PUBLIC

If Multiply Labs can successfully automate the sterile, high-throughput manufacturing of individualized cell therapies, it stands to capture a foundational role in a multi-billion dollar shift towards precision medicine.

The headline opportunity is to become the de facto robotic infrastructure layer for commercial-scale cell and gene therapy (CGT) production. The evidence for this outcome being reachable, not just aspirational, lies in the company's early traction with top-tier pharmaceutical companies. Named partnerships with AstraZeneca, Legend Biotech, and Kyverna Therapeutics [Multiply Labs] signal that its robotic systems are being evaluated for commercial-scale production, a critical step towards becoming a standard component of manufacturing suites. The collaboration with Stanford's Laboratory for Cell and Gene Medicine (LCGM) [Multiply Labs] provides academic validation, while the expanded partnership with Thermo Fisher Scientific [Business Wire, 2024] suggests a path to integration with industry-standard instruments. This combination of blue-chip customer pilots and strategic technology alliances forms a credible foundation for a platform play.

Growth from these initial pilots could follow several concrete paths, each with identifiable catalysts.

Scenario What happens Catalyst Why it's plausible
Therapeutic Franchise Dominance Multiply Labs becomes the go-to automation provider for a specific, high-volume therapy like CD19 CAR-T. A successful commercial-scale deployment for Kyverna's KYV-102 candidate [Multiply Labs, 2025]. The company is already piloting automation for this specific product; success would serve as a powerful reference for other developers in the same therapeutic class.
Geographic Capacity Expansion The company scales its "robotics as a service" model by establishing regional manufacturing hubs in key biopharma clusters. The operational launch and customer onboarding of Multiply Labs Italia in Turin [LinkedIn, retrieved 2026]. The establishment of a European subsidiary is a public step toward building distributed production capacity to serve a global customer base.
Software-Led Ecosystem Lock Digital QC software becomes the required process control layer for any robotic CGT manufacturing line, sold independently of hardware. Achieving regulatory acceptance (e.g., FDA feedback) for the software's CFR Part 11-compliant digital records [Multiply Labs]. The software is already marketed as a standalone product for measurement and control; its compliance features directly address a major pain point in drug approval.

Compounding for Multiply Labs would manifest as a data and protocol flywheel. Each robotic system deployed in a customer's facility executes manufacturing protocols while collecting sensor readings and interactions in real time [Multiply Labs]. This operational data, aggregated across deployments, could be used to continuously refine and validate robotic workflows through imitation learning. Over time, the company's library of pre-validated, software-defined protocols for different cell types and processes would become a significant barrier to entry, reducing the time and risk for new customers to adopt the system. The flywheel is already hinted at in the company's description of using cloud-controlled robots and "imitation learning" to scale [PERPLEXITY SONAR PRO BRIEF].

Quantifying the size of the win requires looking at the value of infrastructure providers in adjacent, high-stakes industries. While no direct public comparable exists for robotic CGT manufacturing, the valuation of companies like Illumina (genomic sequencing infrastructure) or Danaher's life sciences tools segment illustrates the premium placed on enabling technologies in biotech. A more focused scenario analysis suggests the potential. If Multiply Labs captured a 10% share of the automated systems market for the estimated $50+ billion global cell therapy market [a commonly cited industry projection], its addressable revenue could reach the low billions annually. In a successful platform scenario where its systems and software become embedded in a majority of new commercial-scale CGT facilities, the company's value could approach that of other specialized life sciences toolmakers that have achieved multi-billion dollar market capitalizations. This is a scenario-based illustration, not a forecast.

Data Accuracy: YELLOW -- The core opportunity framing is supported by cited customer and partnership announcements. Growth scenarios are extrapolated from these specific, announced milestones. Market size comparisons are based on common industry estimates rather than a single, cited report.

Sources

PUBLIC

  1. [The Pharma Letter] Multiply Labs funding rounds | https://www.thepharmaletter.com/article/multiply-labs-secures-11-1-million-in-early-stage-funding

  2. [MIT News, November 2016] Print me a pill: Multiply Labs makes robots that print customized pills | https://news.mit.edu/2016/print-me-a-pill-multiply-labs-1102

  3. [Multiply Labs] Company website | https://www.multiplylabs.com/

  4. [NVIDIA Blog] AI’s Next Revolution: Multiply Labs Is Scaling Robotics-Driven Cell Therapy Biomanufacturing Labs | https://blogs.nvidia.com/blog/multiply-labs-isaac-omniverse/

  5. [LinkedIn] Multiply Labs company page | https://www.linkedin.com/company/multiply-labs

  6. [Multiply Labs, 2025] Multiply Labs partners with Kyverna Therapeutics to pilot robotic automation for KYV-102 | https://www.multiplylabs.com/news/kyverna-partnership-2025

  7. [Business Wire, 2024] Multiply Labs Expands Collaboration with Thermo Fisher Scientific to Automate Cell Therapy Manufacturing | https://www.multiplylabs.com/2025/09/30/thermo-dynacellect-announcement/

  8. [PERPLEXITY SONAR PRO BRIEF] Company description and product overview | https://www.perplexity.ai/

  9. [Precedence Research, 2024] Cell Therapy Market Size Report | https://www.precedenceresearch.com/cell-therapy-market

  10. [Grand View Research, 2024] Gene Therapy Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/gene-therapy-market

  11. [Allied Market Research, 2024] Gene Therapy Market by Vector Type, Application, and Region | https://www.alliedmarketresearch.com/gene-therapy-market

  12. [Roots Analysis, 2024] ATMP Manufacturing Market | https://www.rootsanalysis.com/reports/advanced-therapy-medicinal-products-manufacturing-market.html

  13. [Y Combinator] Multiply Labs company profile | https://www.ycombinator.com/companies/multiply-labs

  14. [TechCrunch, 2018] TC Sessions: Robotics attendee list | https://techcrunch.com/events/tc-sessions-robotics-2018/attendee-list/

  15. [Forbes, 2019] 50 Women-Led Startups That Are Crushing Tech | https://www.forbes.com/sites/allysonkapin/2019/02/20/50-women-led-startups-who-are-crushing-tech/

Articles about Multiply Labs

View on Startuply.vc